

155 rue d'Eragny, 95000 Neuville-sur-Oise, France

**C €** UK 0197

IVD

BIOPHEN™ LMWH Control Low
REF 223701 CI CII 6 vials x 1 mL

BIOPHEN™ LMWH Control Low CI REF 224301 CI 12 vials x 1 mL

BIOPHEN™ LMWH Control Low CII
REF 224401 CII 12 vials x 1 mL

BIOPHEN™ LMWH Control Plasma
REF 223001 C3 C4 6 vials x 1 mL

BIOPHEN™ LMWH Control C3
REF 223801 C3 12 vials x 1 mL

BIOPHEN™ LMWH Control C4
REF 224201 C4 12 vials x 1 mL

Tél:+33 (0)1 34 40 65 10 Fax:+33 (0)1 34 48 72 36 www.hyphen-biomed.com info@hyphen-biomed.com

English, revision: 11-2023

#### INTENDED USE:

For quality control of Low Molecular Weight Heparin (LMWH) assays, using a quantitative automated method.

This device of in vitro diagnostic use is intended for professional use in the laboratory.

#### SUMMARY AND EXPLANATION:

#### Technical:

These controls are proposed for the quality control of LMWH anti-Xa chromogenic assays in plasma (BIOPHEN™ Heparin LRT). *Clinical:* 

Measuring the heparin concentration in patients' plasma may be used for monitoring the therapy and adjusting drug dosage.

#### REAGENTS:

- CI Lyophilized human plasma containing approximately 0.25 IU/mL of LMWH.
- CII Lyophilized human plasma containing approximately 0.50 IU/mL of LMWH.
- C3 Lyophilized human plasma containing approximately 0.80 IU/mL of LMWH.
- **C4** Lyophilized human plasma containing approximately 1.20 IU/mL of LMWH.

Control plasmas contain stabilizing agents.

The control concentrations may vary slightly from one batch to another. For the assay, see the exact values indicated on the flyer provided with the kit used.

The product is classified as non-hazardous and is not subject to labeling according to EC Regulation No. 1272/2008 [CLP].

### WARNINGS AND PRECAUTIONS:

- Some reagents provided in these kits contain materials of human origin. Whenever human plasma is required for the preparation of these reagents, approved methods are used to test the plasma for the antibodies to HIV 1, HIV 2 and HCV, and for hepatitis B surface antigen, and results are found to be negative. However, no test method can offer complete assurance that infectious agents are absent. Therefore, users of reagents of these types must exercise extreme care in full compliance with safety precautions in the manipulation of these biological materials as if they were infectious.
- Waste should be disposed of in accordance with applicable local regulations.
- Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.
- Summary of Safety and Performance (SSP) is available in the European database on medical devices (see Eudamed public website: <a href="https://ec.europa.eu/tools/eudamed">https://ec.europa.eu/tools/eudamed</a> or on request to HYPHEN BioMed).

## REAGENT PREPARATION:

Gently remove the freeze-drying stopper, to avoid any product loss when opening the vial.

CI CII C3 C4 Reconstitute the contents of each vial with exactly 1 mL of distilled water.

Shake vigorously until complete dissolution while avoiding formation of foam and load it directly on the analyzer following Application Guide instruction.

This plasmatic reagent can be more or less turbid after reconstitution. This turbidity is mainly due to plasma lipids that, after freeze-drying, become "less" soluble and may form a slight deposit. If necessary, let each vial stabilize 10 minutes at room temperature and shake before use.

### STORAGE AND STABILITY:

Unopened reagents should be stored at 2-8°C in their original packaging. Under these conditions, they can be used until the expiry date printed on the kit.

[CI] [CI] [C3] [C4] Reagent stability after reconstitution, free from any contamination or evaporation, and stored closed, is of:

- 7 days at 2-8°C.
- 60 days frozen at -20°C or less\*
- Stability on board of the analyzer: see the specific Application Guide.

\*Thaw only once, as rapidly as possible at 37°C and use immediately.

### REAGENTS AND MATERIALS REQUIRED BUT NOT PROVIDED:

· Laboratory material.

# TRACEABILITY:

Lot to lot variability measured on 3 lots is: %CV ≤ 10%.

Controls are traceable to the WHO (World Health Organization) International Standard of reference for LMWH.

Certificate of traceability and uncertainty is available on the HYPHEN BioMed website:

Uncertainty				
	CI	± 0.02 IU/mL	C3	± 0.03 IU/mL
	CII	± 0.02 IU/mL	C4	± 0.06 IU/mL

#### QUALITY CONTROL:

For quality control of LMWH assays by anti-Xa chromogenic methods, with the BIOPHEN™ Heparin LRT (221011/221013/221015) kits.

The target values are determined from multi-reagent and multi-instrument tests.

The use of quality controls serves to validate method compliance, along with betweenseries assay homogeneity for a given batch of reagents.

Include the quality controls with each series, as per good laboratory practice, in order to validate the test.

If the controls fall outside of the acceptance range, the series of assays must be invalidated and the analyses repeated. Check all system parameters before repeating the series.

# LIMITATIONS:

- If the controls are used under measurement conditions other than those validated by HYPHEN BioMed, the test results may vary. The laboratory is responsible for validating the use of these controls in its own analytical system.
- Any reagent presenting no limpid appearance or showing signs of contamination must be rejected.

## REFERENCES:

1. Gray E. et al. Heparin and low-molecular-weight heparin. Thromb Haemost. 2008.

e-IFU (other languages) are available on www.hyphen-biomed.com. For customer support or Application Guides, please contact your local provider or distributor (see <a href="https://www.hyphen-biomed.com">www.hyphen-biomed.com</a>).

Changes compared to the previous version

The following symbols may appear on the product labeling:

